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Abstract
Naproxen (NAP) is a potent nonsteroidal anti-inflammatory drug (NSAID) with
a favorable cardiovascular profile. However, its long-term use may lead to seri-
ous gastrointestinal and renal side effects. NOSH- (nitric oxide and hydrogen
sulfide) releasing naproxen (NOSH-NAP, AVT-219) belongs to a new class of
anti-inflammatory agents designed to overcome these limitations. We compared
the gastrointestinal safety, anti-inflammatory, analgesic, antipyretic, and antipla-
telet properties of AVT-219 to that of NAP in preclinical animal models. We
also evaluated its anticancer effects in 11 human cancer cell (HCC) lines of six
different tissue origins and in a chemotherapeutic xenograft mouse model of
colon cancer. AVT-219: (1) was orders of magnitude more potent than NAP in
inhibiting the growth of cultured HCC; (2) was safe to the stomach, whereas
NAP caused significant ulceration; (3) showed strong anti-inflammatory, anal-
gesic, antipyretic, and antiplatelet properties comparable to NAP; and (4) NAP
caused a significant rise in plasma tumor necrosis factor-alpha (TNFa), whereas
in the AVT-219-treated rats this rise was significantly less. Mechanistically, AVT-
219 was a strong antioxidant, inhibited cyclooxygenase (COX)-1 and -2, thus
reducing prostaglandin (PG) E2. In xenografts, AVT-219 significantly reduced
tumor growth and tumor mass with no sign of GI toxicity, whereas NAP-treated
mice died due to GI bleeding. AVT-219 displayed considerable safety and
potency in inhibiting HCC growth; was an effective analgesic, antipyretic, anti-
platelet, and anti-inflammatory; and was significantly more efficacious than
NAP in reducing the growth of established tumors in a xenograft mouse model.
Abbreviations
ADT-OH, 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione; H2S, hydrogen sulfide;
LPS, lipopolysaccharide; MDA, malondialdehyde; NAP, naproxen; NO, nitric oxide;
NOSH, nitric oxide and hydrogen sulfide; NSAIDs, nonsteroidal anti-inflammatory
drugs; PGE2, prostaglandin E2; SNAP, S-Nitroso-N-acetyl-penicillamine; SOD,
superoxide dismutase.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the
mainstay in the treatment of pain, fever, and inflamma-
tion. Unfortunately, their long-term use may lead to
life-threatening side effects, mainly gastrointestinal,
cardiovascular, and renal. The gastric damage is as a
result of direct epithelial damage due to their acidic prop-
erties and also through the breakdown of mucosal defense
mechanisms (leukocyte adherence, decreases in blood
flow, and bicarbonate and mucus secretions) due to a
reduction in mucosal prostaglandin (PG) biosynthesis as
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a result of cyclooxygenase-1 (COX-1) inhibition (Wallace
1993, 2008). Among this class of compounds, naproxen is
one of the most cardiovascular-safe drugs because of its
sustained suppression of platelet thromboxane synthesis
(Kearney et al. 2006) and is the one most often recom-
mended for the treatment of osteoarthritis. However, it is
notorious for causing gastrointestinal ulceration and
bleeding.
Regular use of NSAIDs has been associated with lower
incidence of cancer in general, the most compelling data
available to date being that for colon cancer (Kune et al.
1988; Baron et al. 2003; Sandler et al. 2003; Rothwell
et al. 2012). Unfortunately again, potentially life-threaten-
ing side effects alluded to above preclude their widespread
use as chemopreventive agents (Wolfe et al. 1999),
reviewed in Kashfi (2009). In our search for a “better
NSAID”, we developed NOSH-NSAIDs (Kodela et al.
2012, 2013). These are regular NSAIDs, such as aspirin,
naproxen, sulindac, and others, to which nitric oxide-
(NO) and hydrogen sulfide- (H2S) releasing moieties have
been covalently attached. Both NO and H2S are gaseous
signaling molecules of biological importance (Li et al.
2006; Predmore et al. 2012; King et al. 2014). The
rationale for incorporating these gaseous mediators into
NSAID molecules was based on the observations that NO
(Brown et al. 1993; Wallace et al. 1994; Wallace and
Miller 2000) and H2S (Fiorucci et al. 2005; Wallace et al.
2007) have some of the same properties as PGs within
the gastric mucosa, thus modulating some components of
the local mucosal defense systems which should lead to
reduced gastrointestinal toxicity.
In this study, we carried out a head-to-head compar-
ison of the gastrointestinal safety, anti-inflammatory,
analgesic, antipyretic, and antiplatelet properties of
naproxen with those of AVT-219. We also evaluated the
efficacy of naproxen and AVT-219 on established tumors
in a xenograft mouse model of colon cancer.
Materials and Methods
Reagents
NOSH-naproxen (AVT-219) [6-(1-oxo-1-(4-(3-thioxo-3H-
1,2-dithiol-5-yl) phenoxy) propan-2-yl) naphthalen-2-yl
4-(nitrooxy) butanoate] was synthesized as previously
described (Kodela et al. 2013) and was a gift from Avi-
cenna Pharmaceuticals Inc. (New York, NY). Its structural
components are shown in Figure 1. Lipopolysaccharide
(LPS) from Escherichia coli, naproxen, and carrageenan
was purchased from Sigma (St. Louis, MO). The kits used
for determination of PGE2, lipid peroxidation, and super-
oxide dismutase (SOD) were purchased from Cayman
Chemical (Ann Arbor, MI).
Experimental groups and treatments
In all the protocols described below, we used at least five
male Wistar rats per group that weighed 180–200 g. The
rats were obtained from Charles River Laboratories Inter-
national (Wilmington, MA) and were fed standard labo-
ratory chow and water ad libitum. The animals were
housed in suspended, wire-bottom cages in a room main-
tained at 22  2°C, humidity 65–70%, and 12-h light/
12-h dark cycle. All experimental procedures were
approved by our institutional animal research committees
and were performed in accordance with nationally
approved guidelines for the treatment of laboratory ani-
mals. It should be noted that in the anti-inflammatory
and antihyperalgesia studies, the experimenter was
blinded to the treatment protocols; whereas in all the
other protocols the experimenter was not blinded.
Ulcer index
Rats were fasted for 48 h with free access to drinking water.
Naproxen and AVT-219 at equimolar concentrations, 80
and 188 mgkg1, respectively, were administered orally by
gavage suspended in vehicle (0.5% carboxymethylcellulose,
CMC). Six hours post administration, animals were eutha-
nized in a CO2 chamber; stomachs were then removed
immediately, cut along the greatest curvature, and rinsed
with ice-cold distilled water. The ulcer index (UI) was
determined as described by Best et al. (1984) and reported
by us previously (Chattopadhyay et al. 2010; Kodela et al.
2013). Excised tissues from each stomach were flash frozen
in liquid nitrogen for assessing levels prostaglandin E2
(PGE2), malondialdehyde (MDA), and SOD activity. Blood
samples from each rat were taken by cardiac puncture into
heparin-containing vials and used for determination of
plasma tumor necrosis factor-alpha (TNF-a).
PGE2 levels
About 1 g of stomach tissue from each rat was homoge-
nized in 5 mL of 0.1 mol/L phosphate buffer (pH 7.4)
Figure 1. Structural components of AVT-219. The parent compound
naproxen is shown in the shaded box. The parts of the molecule that
releases NO and H2S are shown in the dotted ellipses.
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containing 1-mmol/L EDTA and 10-lmol/L indometha-
cin. The homogenate was then centrifuged for 10 min at
12,000g at 4°C. PGE2 content in the supernatant was
determined in duplicate using an enzyme immunoassay
kit from Cayman Chemical, following the manufacturer’s
protocol. Briefly, 50 lL each of standard or homogenate,
enzymatic tracer, and specific antiserum were mixed.
After overnight incubation at 4°C, the plates were washed
with wash buffer, and Ellman’s reagent (200 lL) was
added to each well. After 1 h of incubation at room tem-
perature, the absorbance was measured at 412 nm. PGE2
levels are expressed as pg mg1 of protein. Protein con-
centration was determined by Biorad assay.
Lipid peroxidation
Levels of MDA were measured as an index of lipid perox-
idation using a colorimetric kit from Cayman Chemical,
as detailed by the manufacturer and reported by us
(Chattopadhyay et al. 2010). Snap frozen stomach tissue
(25 mg) was sonicated for 15 sec at 40 V over ice with
250 lL of radioimmunoprecipitation (RIPA) buffer
(25 mmol/L TrisHCl pH 7.6, 150 mmol/L NaCl, 1%
NP-40, 1% sodium deoxycholate, and 0.1% SDS) with
phenylmethylsulphonyl fluoride (PMSF) as protease inhi-
bitor. Homogenates were centrifuged for 10 min at 200g
at 4°C. Thiobarbituric acid reactant substances (TBARS)
content was then measured in the supernatant and
expressed as nmoles of MDAg1 of protein.
SOD activity
Using a colorimetric kit from Cayman Chemical, we
measured SOD activity in the gastric mucosa by
homogenizing 1 g of tissue in 5 mL of a buffer system
containing 20 mmol/L HEPES (pH 7.2) with 1 mmol/L
EGTA and 300 mmol/L of sucrose solution as reported
previously (Chattopadhyay et al. 2010). SOD activity
was measured spectrophotometrically at 460 nm and
expressed as units (U) activitymg1 protein. One unit
of activity is defined as the amount of enzyme needed
to exhibit 50% dismutaion of the superoxide radical.
Plasma TNF-a level
An enzyme immunoassay kit from R&D systems (Min-
neapolis, MN) was used to measure plasma TNF-a levels
as reported by us (Chattopadhyay et al. 2010; Kodela
et al. 2013). Briefly, fresh blood (50 lL) was incubated
with antibodies specific for rat TNF-a and washed three
times with assay buffer. Following washing of unbound
antibody-enzyme reagent, substrate solution (tetramethyl-
benzidine, TMB, plus hydrogen peroxide) was then
added. The reaction was stopped by adding dilute
hydrochloride acid and its intensity measured at 450 nm.
Sensitivity of this assay was determined by adding 2 stan-
dard deviations to the mean optical density value of
20 9 zero standard replicates and calculating the corre-
sponding concentration; sensitivity is estimated to be
1.6 pgmL1.
Antipyretic activity
Rats received LPS (50 lgkg1) intraperitoneally to induce
fever 30 min after equimolar administration of naproxen
(80 mgkg1) or AVT-219 (188 mgkg1) as described by
Pinto et al. (1998). Rectal temperature was measured by
inserting a lubricated thermistor probe (external diameter:
3 mm) 2.8 cm into the rectum of the animal. The probe
was linked to a digital reader, which displayed the tem-
perature at the tip of the probe (0.1°C). Rectal tempera-
tures were recorded hourly for 5 h.
Determination of anti-inflammatory
response
Rats (n = 5 in each group) were administered vehicle
(1%, CMC in 1 mL), naproxen (80 mgkg1), or AVT-
219 (188 mgkg1) 30 min before inducing inflammation
which was done by subcutaneously injecting carrageenan
(1%, 100 lL, suspended in sterile saline solution) into the
plantar surface of the right hind paw as described by
Winter et al. (1962) and reported by us (Chattopadhyay
et al. 2010; Kashfi et al. 2015). The change in paw volume
before and after carrageenan injection was measured using
a water displacement plethysmometer (Model 520; IITC/
Life Sciences Instruments, Woodland Hills, CA) for 5 h.
At the end of the experiment, rats were euthanized by
asphyxiation in a CO2 chamber. After cutting each hind-
paw at the level of the calcaneus bone, exudates (oedema
fluid) were collected and processed for measurement of
PGE2, as described above.
Hyperalgesia
Hindpaw inflammation was produced by intraplantar
injection of carrageenan (100 lL of 1% carrageenan in
sterile saline solution) into either hindpaw chosen at ran-
dom. Suspensions of naproxen (80 mgkg1), AVT-219
(188 mgkg1), or vehicle (CMC, 0.5% w.v1) were
administered orally 1 h after carrageenan injection, and
the mechanical nociceptive threshold determined 30 min
after this and thereafter every hour for 5 h. The paw
hyperalgesia was measured with an electronic pressure
meter as reported earlier (Chattopadhyay et al. 2010;
Kodela et al. 2013; Kashfi et al. 2015). The animals were
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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tested before and after treatments, the results are
expressed by the delta reaction force (g).
Antiplatelet activity
Collagen-induced platelet aggregation of human platelet-
rich plasma (PRP) occurs through a pathway dependent
upon the arachidonic acid cascade (Nieswandt and Wat-
son 2003). We therefore compared the antiaggregatory
properties of AVT-219 to that of naproxen using this sys-
tem as reported previously (Chattopadhyay et al. 2010;
Kashfi et al. 2015). The antiaggregatory activity of the
two compounds was determined as percent inhibition of
platelet aggregation compared to control samples. IC50
values were calculated by nonlinear regression analysis.
COX enzyme activity
The ability of AVT-219 to inhibit COX-1 and COX-2
enzymatic activity was compared to that of naproxen
using a colorimetric COX (ovine, o-COX) inhibitor
screening kit from Cayman Chemicals as described previ-
ously (Kulmacz and Lands 1983).
Cell culture and MTT
HT-29, SW-480, and HCT-15 human colon adenocarci-
noma, MIA PaCa-2 and BxPC-3 human pancreatic can-
cer, LNCAP human prostate cancer, A549 human lung
cancer, MCF-7 (estrogen receptor positive), MDA-MB
231 and SK-BR-3 (estrogen receptor negative) human
breast cancer, and Jurkat T (human leukemia) cell lines
were obtained from American Type Tissue Collection
(Manassas, VA). All cells lines were grown as previously
described (Kodela et al. 2012). Single-cell suspensions
were obtained by trypsinization (0.05% trypsin/EDTA),
and cells were counted using a hemocytometer. Viability
was determined by the trypan blue dye exclusion method.
Cell growth inhibitory effect of naproxen and AVT-219
was measured using a colorimetric MTT assay kit (Roche,
Indianapolis, IN).
Therapeutic evaluation of NOSH-naproxen in
a mouse xenograft model
Male athymic nude (NU/NU) mice (n = 15), age
5 weeks, were purchased from Charles River Laborato-
ries, Inc. After 1 week of acclimation, the mice were
inoculated subcutaneously in the right flanks with
SW480 human colon cancer cells (3 9 106) suspended
in Matrigel (50% vv1, BD Biosciences, San Jose, CA)
using a 1-mL syringe and 22-gauge needles. When the
tumors reached an average sizes of ~100 mm3 (10 days
post inoculation), the mice were randomly divided into
three groups and gavaged daily with either vehicle
(0.5% CMC) or equimolar (0.18 mmolkg1) concentra-
tions of AVT-219 (100 mgkg1 body weight) or
naproxen (45 mgkg1 body weight). Tumor size was
measured every other day using electronic calipers, and
the tumor volumes were calculated using the following
formula: length 9 width2/2. After 30 days of treatment,
the mice were sacrificed, the tumors collected, weighed,
and photographed. Blood was also collected for deter-
mination of serum NO and H2S levels. The tumors
were stored in formalin for immunohistochemistry
studies.
Immunohistochemistry
All specimens were fixed in formalin and paraffin
enclosed for examination. Five-micrometer-thick tissue
sections were prepared to conduct immunohistochem-
istry using standard techniques as reported by us
(Chattopadhyay et al. 2012). For proliferation we used
primary mouse proliferating cell nuclear antigen
(PCNA) at the appropriate dilution (1:100 dilution),
and for detection of apoptotic cell death in tumor tis-
sues, we used a TUNEL system kit from Promega
(Madison, WI).
Determination of plasma NO and H2S levels
Plasma concentration of NO was quantified indirectly as
the concentration of nitrate (NO3
) and nitrite (NO2
)
by the Griess method using an assay kit from Cayman
Chemical and following the protocol described by the
manufacturer, as reported by us previously (Chattopad-
hyay et al. 2012; Kodela et al. 2012, 2013). Plasma was
filtered using a 10-KD molecular weight cut-off filter
from Millipore (Bedford, MA) before each analysis, to
reduced background absorbance due to the presence of
hemoglobin. After centrifugation for 10 min at
3000 rpm, samples (40 lL/well) were mixed with 10 lL
nitrate reductase mixture and incubated for 3 h after
which Griess reagents 1 and 2 (50 lL each) were added.
Absorbance was read after 10 min at 540 nm using a
plate reader. The concentration of nitrate/nitrite was cal-
culated graphically from a calibration curve prepared
from NaNO2 standard solution.
H2S levels were measured as previously described using
the standard methylene blue method (Li et al. 2007;
Huang et al. 2010), and reported by us (Chattopadhyay
et al. 2012; Kodela et al. 2012, 2013). Plasma (100 lL)
was mixed with distilled water (100 lL), Zinc acetate (1%
w/v, 250 lL), trichloroacetic acid (10% w/v, 250 lL), and
N, N-dimethyl-p-phenylenediamine sulfate (133 lL,
2016 | Vol. 4 | Iss. 2 | e00224
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20 lmol/L) in 7.2 mol/L HCl and FeCl3 (133 lL,
30 lmol/L) in 7.2 mol/L HCl. The absorbance of the
resulting mixture was determined after 15 min using a
96-well microplate reader at 670 nm. H2S levels were cal-
culated against a calibration curve of NaHS (1–250 lmol/
L). Because of the strong acidic conditions, this method
overestimates H2S levels as it measures free H2S, HS

(hydrosulfide anion), S2 (sulfide), acid-labile sulfide, and
other, as yet unidentified, sulfides and can only provide a
rough estimate of H2S production (Olson 2009). There-
fore, our results presented here indicate the sum total of
these species.
Data analysis
All data are presented as the mean  SEM, with sample
sizes of at least 5 rats/mice in each group. Comparisons
among groups were performed using a one-way analysis
of variance followed by the Student t-test.
Results
Naproxen, but not AVT-219, induced GI
damage in rats
Visual inspection showed that there were no gastric
mucosal lesions in vehicle-treated rats (control group,
Fig. 2A and D), for these rats, the gastric damage score
(also described in the literature as “UI”) was zero
(UI = 0). However, all rats treated with naproxen
(80 mgkg1) developed pronounced gastric ulcers and
erosions, UI = 80 (Fig. 2B and D). In contrast, AVT-219
(188 mgkg1) did not induce significant gastric damage
UI = 2 (Fig. 2C and D). This is consistent with previously
published data, where NO (Brown et al. 1993; Wallace
et al. 1994; Wallace and Miller 2000) and H2S (Fiorucci
et al. 2005; Wallace et al. 2007) were shown to act as
mediators in mucosal defense.
Gastric PGE2 content
The main products of cyclooxygenase-mediated arachi-
donic acid metabolism in the gastric mucosa are the PGs.
In that respect, PGE2 levels in the normal mucosal tissue
of the vehicle-treated rats, the naproxen-treated rats, and
the AVT-219-treated rats were 72.3  4.2, 10.2  1.6,
and 22.1  2.6 pgmg1 protein, respectively (Fig. 3A).
That is, a rat treated with naproxen (80 mgkg1) pro-
duced about 86% less PGE2 than rats in the control
group. AVT-219 at an equimolar concentration
(188 mgkg1) reduced PGE2 by about 70%. These com-
parative PGE2 levels showed a clear and significant COX
inhibition by naproxen and AVT-219.
Effects of AVT-219 on suppression of COX
activity
When metabolized, AVT-219 should produce naproxen,
H2S, and NO. Previously, we had shown that NO and
H2S are released from AVT-219 (Kodela et al. 2013). In
order to show the effects of the naproxen component, we
compared the effects of AVT-219 to that of naproxen on
pure ovine COX-1 and COX-2 enzymatic activity. As
shown in Table 1, AVT-219 dose dependently and selec-
tively inhibited the enzymatic activity of COX-1 more
than that of COX-2. Naproxen at 3000 and 6000 lmol/L
concentrations, inhibited COX-1 by 80  4% and
92  3%; and COX-2 by 65  3% and 75  2%. AVT-
219 at 100 and 200 nmol/L inhibited COX-1 by 45  3%
and 54  2%; and COX-2 by 16  2% and 27  3%.
The concentrations of naproxen and AVT-219 chosen in
these studies were based on their respective IC50s for cell
growth inhibition in SW480 colon cancer cell line (see
below). We used indomethacin (1 lmol/L), a nonselective
COX inhibitor (Riendeau et al. 1997), as a reference com-
pound in these studies, which inhibited COX-1 by
69  3% and COX-2 by 70  2% (Table 1).
Effect of AVT-219 on lipid peroxidation and
SOD activity
MDA levels representing oxidative stress in the gastric tis-
sue were 6.5  0.6 nmolmg1 protein for the vehicle-
treated group, this increased to 59  3 nmolmg1 in the
naproxen-treated group, but was only 26  2 nmolmg1
protein in the AVT-219-treated group (Fig. 3B). On the
other hand, SOD activity in the vehicle-treated group was
3.4  0.5 Umg1 protein, this was decreased to
1.4  0.3 Umg1 protein in the naproxen-treated group,
and was significantly increased (compared to the
naproxen group) to 3.6  0.2 Umg1 protein in the
AVT-219-treated group (Fig. 3C).
AVT-219 effectively reduces carrageenan-
induced paw swelling
Naproxen is very effective in treating inflammation and
inflammatory pain. Here, we compared the COX-depen-
dent anti-inflammatory activity of naproxen to that of
AVT-219 using the carrageenan-induced rat paw edema
model (Winter et al. 1962). After inducing inflammation,
animals receiving vehicle showed a fast time-dependent
increase in paw volume, which appeared to be plateauing
toward the end of the experiment after 5 h
(DV = 1.4 mL, Fig. 4A). In contrast, animals receiving
naproxen and AVT-219 showed a weak inflammatory
response (DV = 0.3–0.4 mL by 2 h), which decreased
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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over the next 3 h (Fig. 4A). From hours 3–5, AVT-219
was significantly (P < 0.05) better than naproxen in its
anti-inflammatory action (Fig. 4A). PGE2 is one of the
main products of cyclooxygenase-mediated arachidonic
acid metabolism and is a key mediator of the inflamma-
tory process (Kashfi 2009). Comparison of PGE2 content
of paw exudates showed a clear and significant COX inhi-
bition by naproxen and AVT-219 (Fig. 4B). PGE2 level in
control vehicle-treated rats was 82  3 pgmg1 protein,
and in the naproxen- and AVT-219-treated rats were
9.3  0.3 pgmg1 protein and 32  2 pgmg1 protein,
respectively. This is equivalent to reduction of 89% and
61% by naproxen and AVT-219, respectively.
Plasma TNF-a levels are lower in AVT-219-
treated rats
The proinflammatory cytokine TNF-a in plasma of
naproxen-treated rats was increased by about 14-fold.
Plasma TNF-a levels were 11  0.3 pgmL1 in vehicle-
treated rats and 150  2 pgmL1 in the naproxen-
treated rats (Fig. 5). The corresponding value in
Figure 2. AVT-219 does not cause gastric damage. Naproxen (80 mgkg1) and AVT-219 (188 mgkg1) were administered orally at equimolar
concentrations (0.35 mmolkg1) and effects on the stomach were evaluated as indicated in “Ulcer index”. (A) Stomach of a vehicle-treated rat;
(B) stomach of a naproxen-treated rat showing ulceration and bleeding; (C) stomach of a AVT-219-treated rat which is essentially devoid of
ulcers; and (D) gastric damage due to naproxen, UI = 80  5 mm (†P < 0.01 compared to vehicle), AVT-219, UI = 2  0.4 mm (*P < 0.01
compared to naproxen).
Figure 3. Effects of AVT-219 and naproxen on gastric PGE2 level, lipid peroxidation (MDA), and superoxide dismutase (SOD). Three groups of
rats were treated with vehicle, equimolar concentrations of AVT-219, and naproxen and their stomachs were removed and processed as
described in “PGE2 levels”. AVT-219 and naproxen caused significant reductions in gastric mucosal PGE2 levels (A). Results are mean  SEM of
five rats in each group, *P < 0.05 versus vehicle group, §P < 0.05 versus AVT-219 group. Naproxen caused an almost nine fold increase in MDA
levels, for AVT-219-treated rats, MDA levels were about 2.3-fold higher (B). Results are mean  SEM for five rats in each group, *P < 0.01 versus
vehicle group, †P < 0.01 versus naproxen group. Naproxen caused a 2.4-fold reduction in SOD activity, whereas AVT-219 had no effect (C).
Results are mean  SEM of five rats, †P < 0.05 versus vehicle group, *P < 0.01 versus naproxen group.
2016 | Vol. 4 | Iss. 2 | e00224
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AVT-219-treated rats was 50  3 pgmL1, this repre-
sents a three fold reduction compared to the native com-
pound.
Antipyretic activity of AVT-219
NSAIDs in general have a moderate antipyretic effect
when administered orally. Here, we compared at equimo-
lar doses (0.34 mmolkg1) the effects of AVT-219
(188 mgkg1) to that of naproxen (80 mgkg1) on LPS-
induced fever in rats. Both agents were administered (po)
30 min before injecting LPS (50 lg/kg ip). Vehicle-treated
rats showed a time-dependent increase in body tempera-
ture (DT = 1.9  0.1°C) which peaked at 3 h and then
slowly declined by about 0.2°C over the next 2 h
(Fig. 6A). Naproxen- and AVT-219-treated rats showed
only about 0.3–0.4°C increase in body temperature within
the first 30 min which fell down to 0.15–0.25°C by 1 h
after LPS injection and continuously declined for the next
4 h, in fact at the end of the experiment the AVT-219-
treated rats showed no detectable fever (Fig. 6A).
AVT-219 is an effective analgesic
This assay measures the ability of a test drug to reverse
hyperalgesia (decreased threshold to a painful stimuli)
produced by injection of carrageenan. The mechanical
pain threshold was increased in a time-dependent manner
after administering naproxen or AVT-219 (Fig. 6B). Pain
threshold before administration of naproxen or AVT-219
ranged from 62 to 70 g. This was reduced to about 10 g
after carrageenan injection confirming a higher sensitivity
to mechanical stimuli (nonpainful at normal conditions).
The mechanical threshold for pain increased to about
32 g in both naproxen- and AVT-219-treated groups.
Antiplatelet properties of AVT-219
Antiaggregatory effects of naproxen and AVT-219 were
studied on collagen-induced platelet aggregation of
human PRP. The results expressed as IC50 are shown in
Figure 6C. Analysis of the data, which represents the
mean  range for two different individuals, does not lend
Table 1. AVT-219 inhibits cyclooxygenase enzyme activity.
Treatment
COX-1
% inhibition
COX-2
% inhibition
NAP, 3000 lmol/L 80  4 65  3
NAP, 6000 lmol/L 92  3 75  2
AVT-219, 100 nmol/L 45  3 16  2
AVT-219, 200 nmol/L 54  2 27  3
Indomethacin, 1 lmol/L 69  3 70  2
Pure ovine COX enzymes were treated with NAP or AVT-219 at their
respective 1 9 IC50 and 2 9 IC50 for cell growth inhibition in SW480
colon cancer cell line for 15 min at 4°C after which o-COX-1 and o-
COX-2 enzyme activity was determined. Results are mean  range of
two independent studies performed in duplicate.
Figure 4. AVT-219 has effective anti-inflammatory properties. Rat paw edema was induced by carrageenan injection as described in
“Determination of anti-inflammatory response”. AVT-219 caused a significant reduction in paw volume at all time points, whereas naproxen’s
anti-inflammatory action became significant after 2 h; further AVT-219 from 3 to 5 h was significantly better than naproxen in its anti-
inflammatory action (A). Results are mean  SEM of five rats in each group, †P < 0.05 versus vehicle-treated rats; *P < 0.05 versus naproxen 3–
5 h. In the paw exudate, naproxen reduced PGE2 levels by about 88% and AVT-219 by about 60% (B). Results are mean  SEM for five rats in
each group, †P < 0.01 versus vehicle, §P < 0.05 versus AVT-219.
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itself to any statistical analysis; however, based on the
ranges, there does not appear to be any differences
between the two groups.
AVT-219 inhibits the growth of various
human cancer cell lines
We evaluated the effects of naproxen and AVT-219 on
the growth properties of eleven different human cancer
cell lines of six different histological subtypes. The cell
lines were that of colon (HT-29: COX-1 and COX-2 posi-
tive, HCT 15: COX-null, and SW480: COX-1 positive,
low levels of endogenous COX-2), breast (MCF7: [ER
(+)], MDA MB-231, and SKBR3: [ER()]); pancreatic
(BxPC3: both COX-1 and COX-2 positive, MIAPaCa-2:
COX-null), lung (A549), prostate (LNCaP), and T-cell
leukemia (Jurkat). AVT-219 was very effective in inhibit-
ing the growth of these cell lines (Table 2). The IC50s for
cell growth inhibition at 24 h for AVT-219 ranged from
0.09  0.01 to 0.14  0.02 lmol/L and that for naproxen
was 2100  200 to 3110  185 lmol/L. In a fold com-
parison of the IC50 values (naproxen/AVT-219), AVT-219
was at least 18,000-fold to 33,000-fold more potent than
naproxen in various cell lies (Table 2). It should be noted
that the data presented for HT-29, MCF-7, BxPC3, and
Jurkat cells are replication of our previously published
work (Kodela et al. 2013).
Efficacy of AVT-219 in established tumor
xenografts in nude mice
Male athymic nude (NU/NU) mice were injected subcuta-
neously with SW480 colon cancer cells in the right flank,
allowing for the development of subcutaneous tumors
with an average volume of about 100 mm3 after 10 days.
Following tumor formation, the mice were divided into
three groups. The control group was treated with the
vehicle (0.5% CMC); the other two groups were treated
orally with equimolar (0.18 mmolkg1) concentrations of
naproxen (43 mgkg1) and AVT-219 (100 mgkg1). All
Figure 5. Plasma TNF-a levels are lower in AVT-219-treated rats. Rats
were treated with equimolar concentrations (0.35 mmolkg1) of
naproxen and AVT-219 and plasma TNF-a were measured as
described in “Plasma TNF-a level”. Naproxen increased plasma TNF-a
by about 14-fold, whereas this rise was about 3-fold in AVT-219-
treated rats. Results are mean  SEM for five rats in each group,
*P < 0.001 versus vehicle, §P < 0.01 versus naproxen.
Figure 6. AVT-219 reduces LPS-induced fever, increases the threshold for pain, and has antiplatelet activity. (A) LPS (50 lgkg1, i.p.) was
administered to the rats 30 min after naproxen and AVT-219 administration. Core body temperature was recorded at 30 min and thereafter
hourly for 5 h. Results are mean  SEM for five rats in each group, *P < 0.01 versus vehicle for both naproxen and AVT-219 from 1 to 5 h. (B)
Mechanical pain threshold was increased as a function of time by AVT-219 and naproxen. Results are mean  SEM for five rats in each group.
*P < 0.05 versus vehicle for AVT-219 and naproxen 2–5 h. (C) AVT-219 and naproxen were equally effective in inhibiting human platelet
aggregation. Results are mean  range for two individuals.
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the mice treated with naproxen died within 2 weeks from
what appeared to be sever GI bleeding and damage to the
spleen and liver. However, the AVT-219-treated mice did
not show any overt signs of toxicity, their average group
weight was comparable to that of the controls. After
30 days of treatment (protocol shown in Fig. 7A), the
AVT-219-treated mice (Figs. 7C and 8A) showed a con-
siderable reduction in tumor growth compared with
untreated mice (Figs. 7B and 8A). The stomachs of the
AVT-219-treated mice were completely devoid of any GI
erosions or bleeding (Fig. 7D). Compared with the con-
trol group with a mean tumor volume of
2100  380 mm3, AVT-219-treated mice had a tumor
volume of 370  50 mm3, equivalent to a mean reduc-
tion of 82% (P < 0.05). Compared to the control group
with average tumor mass 1.4  0.5 g, AVT-219 reduced
the tumor mass to 0.63  0.11 g, equivalent to a reduc-
tion of 55% (P < 0.05) which was relatively consistent
with continued regression of tumor growth over the same
treatment period. Immunohistochemical analysis of AVT-
219-treated and untreated mouse tumor sections was
evaluated by PCNA, which is a biomarker for prolifera-
tion, and by TUNEL to determine the number of cells
undergoing apoptosis. The vehicle-treated tumors showed
a strong expression index for PCNA (80  3%, Fig. 9A
and C), whereas AVT-219-treated tumors showed a
diminished expression of PCNA (20  0.5%, Fig. 9B and
C). TUNEL-positive cells in the vehicle-treated tumors
were 1.5  0.4% (Fig. 9D and F); AVT-219 increased
apoptosis in the tumors (83  3%) as measured by
TUNEL staining for multiple tissue sections (Fig. 9E and
F). Therefore, AVT-219 suppressed tumor growth by a
combination of increased apoptosis and reduced cell pro-
liferation.
AVT-219 releases both NO and H2S in vivo
AVT-219 was designed to release both NO and H2S. To
that end, using in vitro and in vivo protocols, we had
previously shown that indeed that was the case (Kodela
et al. 2013). Here, using yet another in vivo model, that
is, in the mice bearing the colon cancer xenografts, we
have confirmed our previous finding showing that both
NO and H2S were significantly higher in the AVT-219-
treated animals (Figure 10). It should be noted that the
serum concentrations of H2S as determined by the methy-
lene blue method described in “Determination of plasma
NO and H2S levels” are not accurate, as this method is
associated with considerable artifact (Olson 2009). What
our data show are not absolute H2S levels in the serum,
but there appears to be an increase in some form of sul-
fide species (H2S + HS
 + and S2 + others) that must
clearly be due to the administered AVT-219.Ta
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Discussion
In this study, we evaluated the effects of a novel NO- and
H2S-releasing derivative of one of the most commonly
used NSAIDs, naproxen. AVT-219 exhibited all the classic
pharmacological profiles of its native compound, the so-
called four “A”s that is analgesic, antipyretic, anti-inflam-
matory, and antiplatelet aggregation. One of the most
Figure 7. Efficacy of AVT-219 in established tumor xenografts. Study protocol: (A) Male athymic nude mice were injected subcutaneously with
SW480 colon cancer cells in the right flank, after 10 days average volume was about 100 mm3. Following tumor formation, the mice were
divided into three groups and treated daily by gavage with the vehicle (0.5% CMC, B), or equimolar concentrations of AVT-219 (100 mgkg1,
C) or naproxen (43 mgkg1). Naproxen-treated mice died within 2 weeks. (D) Stomachs of the AVT-219-treated mice showing no signs of GI
erosions or bleeding.
Figure 8. AVT-219 reduced tumor growth and tumor mass. Animals were treated as depicted in Figure 7. Average tumor volume as function of
time and tumor mass at sacrifice are shown in A and B, respectively. AVT-219 significantly reduced tumor growth from day 15 of treatment to
sacrifice, *P < 0.01. Tumor mass was also significantly reduced by AVT-219 treatment, *P < 0.01. Naproxen-treated mice died within 2 weeks of
treatment.
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significant side effects associated with naproxen is its GI
toxicity, which limits its use. AVT-219 was designed to
overcome this side effect and be a safer naproxen by
releasing NO and H2S, two gasotransmitters of physiolog-
ical relevance that have been shown to be important
mediators of gastric mucosal protection (Brown et al.
1993; Wallace et al. 1994, 2007; Wallace and Miller 2000;
Fiorucci et al. 2005). In our comparative study at
equimolar concentrations, AVT-219 did not produce any
significant GI injury despite inhibiting mucosal PGE2 syn-
thesis, whereas naproxen caused a tremendous amount of
GI bleeding. This GI injury is as a result of COX-1 inhibi-
tion. We further confirmed that both compounds dose
dependently inhibited ovine COX-1 and COX-2 enzy-
matic activity in vitro. Our data clearly indicated that
AVT-219 selectively inhibited COX-1 versus COX-2,
whereas naproxen essentially inhibited both COX iso-
forms quite effectively. Another COX-1-mediated effect
that we evaluated was the antiaggregatory effects of
naproxen and AVT-219, which showed that both drugs
had similar antiplatelet effects. On the other hand AVT-
219 was just as effective as naproxen if not better in
reducing LPS-induced fever, and exhibited potent anti-
inflammatory properties using the carrageenan paw
edema model, both of which are COX-2-mediated effects.
Therefore, although in vitro AVT-219 selectively inhibited
COX-1, its effects in vivo are consistent with actions that
are mediated by both COX isoforms. In this regard there
are two important observations to be made: one, it is
important to exercise caution when applying in vitro data
to any in vivo settings; two, as AVT-219 is more potent
than naproxen in many of its actions, released NO and
H2S must contribute to its overall pharmacological
properties.
Analysis of gastric tissue showed that naproxen reduced
SOD activity by about three fold, whereas AVT-219 essen-
tially had no effect on the activity of this antioxidative
enzyme. This may explain in part the high levels MDA,
an index of lipid peroxidation, seen in the naproxen-trea-
ted groups. We also observed that naproxen caused
increases in the circulating levels of the proinflammatory
mediator TNF-a, this may release oxygen-derived free
radicals and proteases by triggering the adherence and
activation of leukocytes, thus producing epithelial injury
(Perini et al. 2004). It has been reported that leukocyte
adherence is an early key event in the pathogenesis of
mucosal injury associated with NSAIDs (Wallace 1993).
Both NO (Wallace and Miller 2000) and H2S (Zanardo
Figure 9. AVT-219 inhibits proliferation and induces apoptosis in vivo. Stored tumors were sectioned, probed, and scored as described in
“Immunohistochemistry”. Average mitotic index at sacrifice was determined by PCNA staining (P < 0.05) and TUNEL staining (P < 0.02).
Representative fields used for quantification of the staining are shown. The scale bar represents 200 lm.
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et al. 2006), two components of AVT-219, are potent
inhibitors of leukocyte adherence induced by NSAIDs,
thus contributing to its GI safety profile.
Naproxen is often used to treat inflammatory condi-
tions. We therefore compared the anti-inflammatory pro-
file of AVT-219 to that of naproxen using the in vivo
carrageenan-induced rat paw edema model. AVT-219
exhibited significantly better anti-inflammatory activity
compared to naproxen. Of note is the observation that
naproxen reduced PGE2 levels to a greater extent in the
paw exudate compared to AVT-219, but that mice treated
with equimolar concentrations of AVT-219 had better
anti-inflammtory response. These observations suggest a
strong role by NO and H2S, which we know are released
by AVT-219 (Kodela et al. 2013), in modulating the anti-
inflammatory response.
Naproxen is also employed in treatment of pain. We
therefore compared the analgesic effect of AVT-219 to
that of naproxen in an in vivo model of hyperalgesia
(Chattopadhyay et al. 2010). Both drugs were equally
effective in increasing the threshold response to a painful
stimulus. These results are in line with our recent reports
showing both NOSH-aspirin (Kodela et al. 2015) and
NOSH-sulindac (Kashfi et al. 2015) to have equal anal-
gesic efficacy to that of their respective native NSAID.
The enhanced antinociceptive effect of AVT-219 may be
due to its ability to reduce the production of proinflam-
matory cytokines, such as IL-1b, and restore neuronal
sensitization caused by PGE2 through upregulation of
KATP channels, as was observed with NOSH-aspirin but
not with aspirin (Fonesca et al. 2015).
In United States, colorectal cancer (CRC) is one of the
top three most common cancers in both men and
women, resulting in an estimated 50,000 deaths this year
alone (American-Cancer-Society, 2015). Epidemiological
data show NSAIDs as the prototypical class of drugs that
prevent CRC (Harris et al. 2005). While aspirin is the
NSAID that has been investigated the most (Baron et al.
2003; Sandler et al. 2003; Rothwell et al. 2012), other
NSAIDs including naproxen are also effective anticancer
agents (Harris et al. 2008). In this study we first showed
that AVT-219 was orders of magnitude more potent than
naproxen in inhibiting the growth of adenomatous,
epithelial, and lymphocytic cancer cell lines; that is, eleven
cell lines originating from six different tissues. Thus,
demonstrating a generalized property that was tissue-type
independent. Recently we reported that this growth inhi-
bition was as a result of reductions in cell proliferation,
G0/G1 cell-cycle arrest, leading to increased apoptosis
(Kodela et al. 2013). The underlying mechanism(s) for
the enhanced potency of AVT-219 observed in these stud-
ies is not known, but must be due to contributions from
both NO and H2S. While we do not know anything about
the kinetics of NO and H2S release and their potential
interactions, we do know that in vitro both contribute
toward the potency of the intact molecule. This is based
on our recent report where we showed that the biological
activity of naproxen plus SNAP (releases NO) plus ADT-
OH (releases H2S) was not as same as the biological activ-
ity of the intact NOSH-naproxen (AVT-219) molecule
(Kodela et al. 2013), thus the sum of parts did not equal
the whole. NO can also react with H2S to produce
HSNO, which is a highly reactive intermediate (Filipovic
et al. 2012; Cortese-Krott et al. 2015). Furthermore, NO
and H2S signaling pathways appear to be intimately inter-
twined with mutual potentiation of biological responses
(Cortese-Krott et al. 2015).
In this study, we also compared the efficacy of AVT-
219 to that of naproxen at equimolar concentrations on
established tumors using an in vivo xenograft mouse
model of colon cancer. AVT-219 treatment resulted in
large reductions in tumor volume and mass. Decrease in
tumor size and mass was associated with inhibition of cell
proliferation and induction of apoptosis. The dose of
AVT-219 used in this mouse model was well tolerated
with no apparent harmful side effects or overall gross tox-
icity; the mice in both control and AVT-219-treated
groups had similar average body weights at necropsy and
visual inspection of the organs did not show anything
untoward. However, all the naproxen-treated mice died
Figure 10. NO and H2S levels are increased in vivo after
administration of AVT-219. Plasma concentration of NOx and H2S
prepared at the end of the xenograft studies was quantified as
described in “Determination of plasma NO and H2S levels”. Results
are mean  SEM for five mice in each group. †P < 0.001 versus
vehicle.
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by the end of the second week of treatment from what
appeared to be GI bleeding and damage to other organs
such as the spleen and the liver. In this regard, further
work is necessary to establish the safe limit for long-term
administration of naproxen in such an animal model and
then compare its efficacy with equimolar concentrations
of AVT-219.
In summary, AVT-219 retains all the classic therapeu-
tic profile of native naproxen, such as the ability to
inhibit inflammatory response, nociception, platelet
aggregation, and fever, but spares the GI tract. It has
all the attributes that make it an ideal promising alter-
native to existing therapies for the treatment of inflam-
mation and pain. AVT-219 may also prove useful either
alone or in combination with other classical chemother-
apeutic agents in treatment of colon and possibly other
cancers. Current work is directed toward unraveling the
molecular targets of AVT-219 in different in vivo
models of colon cancer and further evaluating its safety
profile.
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